A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients by Solomkin, JS et al.
Review
A consensus statement on empiric therapy for suspected gram-positive
infections in surgical patients
Joseph S. Solomkin, M.D.a,b,*, H. Stephen Bjornson, M.D., Ph.D.b,
Miguel Cainzos, M.D., Ph.D.c, E. Patchen Dellinger, M.D.d, Lorenzo Dominioni, M.D.e,
Robert Eidus, M.D., M.B.A.f, Eugen Faist, M.D.g, David Leaper, M.D.h,
James T. Lee, M.D., Ph.D.i, Pamela A. Lipsett, M.D.j, Lena Napolitano, M.D.k,
Carl L. Nelson, M.D.l, Robert G. Sawyer, M.D.m, John Weigelt, D.V.M., M.D.n,
Samuel Eric Wilson, M.D.o
aDivision of Trauma and Critical Care, University of Cincinnati College of Medicine, Cincinnati, OH, USA
bDepartment of Surgery, Division of Trauma/Critical Care, University of Cincinnati College of Medicine, 231 Albert B. Sabin Way, Cincinnati, OH
45267-0558, USA
cMedical School of the University of Santiago de Compostela and Hospital General de Galicia, Santiago de Compostela, Spain
dDivision of General Surgery, University of Washington Medical Center, Seattle, WA, USA
eCenter for Thoracic Surgery, University of Insubria, Ospedale di Circolo di Varese, Varese, Italy
fEinstein Practice Plan, Philadelphia, PA, USA
gUniversity of Munich, Klinikum Grosshadern, Munich, Germany
hProfessorial Unit of Surgery, University of Newcastle upon Tyne, North Tees Hospital, Stockton on Tees, United Kingdom
iSpecialty Care Patient Service Line, Department of Veterans Affairs Medical Center, Minneapolis, MN, USA
jDepartment of Surgery, The Johns Hopkins University School of Medicine and Surgical Intensive Care Units, The Johns Hopkins Hospital, Baltimore, MD, USA
kSurgical Intensive Care Unit, Veterans Administration Hospital, Baltimore, MD, USA
lUniversity of Arkansas, Little Rock, AK, USA
mUniversity of Virginia Health Sciences Center and University Hospital West, Charlottesville, VA, USA
nDepartment of Surgery and the Division of Trauma and Critical Care, Medical College of Wisconsin, Milwaukee, WI, USA
oDepartment of Surgery, University of California Irvine College of Medicine, Orange, CA, USA
Manuscript received August 19, 2002; revised manuscript March 3, 2003
Abstract
Background: Multidrug resistance among gram-positive pathogens in tertiary and other care centers is common. A systematic decision
pathway to help select empiric antibiotic therapy for suspected gram-positive postsurgical infections is presented.
Data sources: A Medline search with regard to empiric antibiotic therapy was performed and assessed by the 15-member expert panel. Two
separate panel meetings were convened and followed by a writing, editorial, and review process.
Conclusions: The main goal of empiric treatment in postsurgical patients with suspected gram-positive infections is to improve clinical
status. Empiric therapy should be initiated at the earliest sign of infection in all critically ill patients. The choice of therapy should flow from
-lactams to vancomycin to parenteral linezolid or quinupristin-dalfopristin. In patients likely to be discharged, oral linezolid is an option.
Antibiotic resistance is an important issue, and in developing treatment algorithms for reduction of resistance, the utility of these new
antibiotics may be extended and reduce morbidity and mortality. © 2004 Excerpta Medica, Inc. All rights reserved.
Keywords: Methicillin-resistant staphylococci; Gram-positive infection; Antibiotic resistance; Empiric treatment; Postsurgical infections; Linezolid; -
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Gram-positive organisms have emerged as prominent
pathogens in nosocomial and postoperative infections. Co-
agulase-negative staphylococci (CoNS), Staphylococcus
aureus, and enterococci now account for 50% to 60% of the
cases of nosocomial bacteremia (Fig. 1) [1,2]. These data
reflect the increasing incidence of infections caused by
gram-positive pathogens in Europe and North America
since the mid-1970s [3].
Multidrug resistance among gram-positive pathogens has
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increased to the point of being a common finding in many
centers. The development of such resistance is an important
clinical problem because of the potential risk of providing
inadequate empiric therapy and because more complex anti-
infective regimens may be required to control these infec-
tions. Success rates in the management of gram-positive
infections in postsurgical patients are improved by early
therapy with agents active against the organisms subse-
quently identified by appropriate culture and susceptibility
testing. This is supported by clinical studies in patients with
ventilator-associated pneumonia, peritonitis, bacteremia,
and meningitis, where provision of inadequate therapy is
closely correlated with adverse patient outcomes, including
increased rates of hospital mortality [4–8].
There are several reasons for the appearance of -lactam
resistant gram-positive organisms in hospital settings. The
wide use of agents with high potency against gram-negative
organisms but considerably less activity against gram-pos-
itive pathogens has contributed significantly to the emer-
gence of resistance. Such reduced activity allows for pro-
longed exposure of initially susceptible organisms to
suboptimal concentrations of -lactams, a situation facili-
tating selection of resistant strains.
Methicillin resistance refers collectively to -lactam re-
sistance and may be conferred either by the production of
-lactamases or through production of low-affinity penicil-
lin-binding proteins (PBPs), inhibiting antibiotic interaction
with the bacterial cell membrane and subsequent bacteri-
cidal activity. All strains of methicillin-resistant S aureus
(MRSA) produce such altered PBPs, such as PBP2 or
PBP2a [9]. The production of PBPs is regulated by a cluster
of chromosomal genes, making the expression of resistance
a chromosomally-mediated phenomenon [10]. Most strains
of MRSA are also resistant to multiple drugs, particularly to
aminoglycosides.
Antibiotic options in the treatment of resistant gram-
positive cocci
The glycopeptide vancomycin has been the antibiotic of
choice for -lactam resistant gram-positive organisms.
However, the utility of this agent has diminished with the
increasing incidence of vancomycin-resistant enterococci
(VRE), the appearance of vancomycin-resistant S aureus
(VRSA) [11], and glycopeptide-intermediate or vancomy-
cin-intermediate S aureus (GISA/VISA) [12]. Current in-
formation on the incidence of vancomycin-resistant organ-
isms may be obtained from www.cdc.gov. Additionally,
heterogeneous resistance to vancomycin has been reported
in MRSA isolates from nosocomial and surgical infections
[13–15]; this may be an additional explanation for thera-
peutic failure with vancomycin in MRSA infections. Such
developments suggest that empiric therapy with newer
agents with different mechanisms of actions, such as the
streptogramin combination, quinupristin/dalfopristin (Q/D),
and the oxazolidinone, linezolid, will be important in the
treatment of such infections.
Fig. 1. Percentage of pathogens reported at selected sites of nosocomial infection for patients in combined medical-surgical intensive care units, National
Nosocomial Infection Surveillance System, 1992–1998 [2]. (CV infect  cardiovascular infection; SSI  surgical-site infection; UTI  urinary tract
infection; pneu  pneumonia; BSI  bloodstream infection; CoNS  coagulase-negative staphylococci; enteroc  enterococci; gram-neg org 
gram-negative organism.)
135J.S. Solomkin et al. / The American Journal of Surgery 187 (2004) 134–145
However, there are important consequences of providing
needlessly broad empiric therapy. Aside from the cost of
combination regimens needed to cover the broad range of
possible infecting microorganisms, there is risk of coloni-
zation with a resistant flora in the patient so treated [16]. In
particular, restriction of vancomycin has been urged as a
means of reducing the incidence of vancomycin resistance
[17].
The consensus panel approach
The increasing frequency of multidrug resistant gram-
positive organisms in postsurgical infections and the avail-
ability of an expanding number of agents active against
these organisms produce an array of decisions regarding the
appropriate empiric management of suspected gram-posi-
tive infections for a particular patient. To define and address
the decisions involved in the management of suspected or
proven gram-positive infections, an expert panel was con-
vened.
The goal of the panel was to develop a treatment algo-
rithm based on available evidence as extracted from Med-
line searches. A preliminary survey of the literature indi-
cated a dearth of randomized, controlled trials with regard to
empiric antibiotic therapy in general and a lack of prospec-
tive treatment data relating to specific antibiotics. While the
panel recognized the importance of the development of
evidence-based guidelines, it acknowledged the paucity of
data in this area and, considering the critical public health
issues in infectious disease and antibiotic resistance, de-
cided to develop a treatment algorithm based on evidence
from retrospective studies and reviews. Where published
evidence was insufficient for clear definition, the collective
experience of the 15-member panel was used to identify
reasonable strategies for patient management through con-
sensus. Two separate panel meetings were convened and
followed by a writing and review process.
The purpose of this article is to present a systematic
decision pathway to aid in the clinical selection of antibi-
otics as empiric therapy for suspected gram-positive post-
surgical infections.
The decision tree
The decision tree describes the flow of events and man-
agement decisions that must be made once it has been
determined to treat a patient for a suspected gram-positive
infection. Fig. 2 is a flow chart presenting the sequence of
events, while the text provides the criteria and evidence for
each decision. The decision tree also identifies specific
Fig. 2. The decision tree for treatment of a patient suspected of having a gram-positive infection. *Institutional risk for VRE 10%, no individual risk for
VRE. †Institutional risk for VRE 10% or individual risk for VRE present. ‡Lack of response assumes no drainable abscess or removable infected device.
(MRSA  methicillin-resistant Staphylococcus aureus; ESRD  end-stage renal disease; vanco  vancomycin; gen.  generation; VRE  vancomycin-
resistant enterococci; pt  patient.)
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questions that should be asked and includes treatment op-
tions for possible answers.
Because of the wide variety of infections that may occur
in a postsurgical patient, the elements of an appropriate
work-up for each patient will not be detailed. It is important
to note, however, that every effort should be made to culture
suspected sources of infection. Appropriate techniques for
obtaining samples have been described in guidelines for
catheter-related infections [18], surgical site infections [19],
and ventilator-associated pneumonia [20].
The costs of delaying therapy until results of culture and
susceptibility testing are available for patients not experi-
encing life-threatening illnesses are less severe, and the
physician may decide to continue observation or conduct
further diagnostic evaluation. An important concern, how-
ever, remains the consequences of delayed treatment of S
aureus bacteremia [8,21]. There is abundant evidence that
staphylococcal bacteremia causes a variety of infectious
complications, including metastatic abscess formation and
endocarditis [22]. Current evidence would support a 10 to
15 day treatment course for patients whose bacteremia and
clinical illness clear within 3 days of catheter discontinua-
tion and antibiotic therapy [23,24].
Given the above data and understanding the need to
avoid overexposure to antibiotics, the panel recommends
that empiric therapy be instituted in patients with underlying
illness who demonstrate evidence of infection or in whom
the risk of waiting for a definitive culture result is greater
than the risk of early intervention. In such patients, empiric
antibiotic therapy should be instituted early and with an
antimethicillin-resistant staphylococcal (MRS) agent. In pa-
tients in whom presumed infections are likely to include
gram-negative bacteria or fungi, coverage for these patho-
gens should also be included.
Institutional prevalence considerations
Determining the threshold incidence of MRSA that war-
rants empiric antibiotic therapy for resistant organisms is a
complex decision based upon a variety of factors. These
factors include the prevalence rates of MRSA, GISA, and
VRE at the specific hospital, the consequences of inade-
quate empiric therapy in the particular patient, the acquisi-
tion costs of potentially usable therapeutic agents, the dif-
ferential efficacy of these agents, the risk of induction of
resistance, and the general and patient-specific toxicities of
each agent. It must be emphasized that any cut-off point is
arbitrary and the physician’s judgment and assessment of
institutional factors and patient risk should always play a
central role in decision-making.
There is currently no evidence to support any definitive
cut-off point applicable to all patients. It is the consensus of
the expert panel that prevalence rates for MRSA 20%
should be considered high, and the risk to the individual
patient of treatment failure becomes substantial (Fig. 2).
This issue is, however, rapidly becoming moot. The spread
of methicillin resistance is truly remarkable. In 1981, 5% of
all S aureus isolates from patients in large teaching hospitals
were methicillin resistant. By 1991, this number had in-
creased to 38% [25]. The latest NNIS data indicate that
methicillin resistance is as high as 54%, an increase of 40%
in just 4 years. As the SCOPE (Surveillance and Control of
Pathogens of Epidemiologic Importance) data indicate,
there is both regional and intrainstitutional variation in the
distribution of such resistant pathogens [1]. Rates are cur-
rently highest in the eastern United States. Within hospitals,
it appears that the general surgical and cardiothoracic ser-
vices have the highest proportions of MRSA (40%). Thus,
geographic and intrainstitutional considerations must be
factored into any risk assessment.
Individual risk-factor considerations
When institutional prevalence rates of MRSA are low
(20%), the choice of antibiotic therapy may be a synthetic
penicillin such as nafcillin. The -lactam antibiotics are the
drugs of choice for staphylococcal infections [26]. How-
ever, when individual risk factors for MRSA infection are
present, the choice of antibiotic should shift to vancomycin,
Q/D, or linezolid. Table 1 provides a list of patient- and
treatment-related factors that increase individual risk of
MRSA infection and mortality and include factors such as
Table 1
Risk factors
Risk factors for MRSA infection
Patient related
Known colonization, including nasal colonization
Obesity
End-stage renal disease
Immunosuppressive therapy
Diabetes mellitus [77]
Spinal cord injury
Liver failure
Anergy
Open chronic wounds [78–80]
Organ system failure score 1 [81] (intraabdominal infection)
Treatment related
Previous antibiotic therapy [49]
Hospital LOS 2 weeks [49,82]
Invasive procedure [82]
Intravascular catheterization, particularly with central venous catheters
[82,83]
Long-term care facilities [84]
Prolonged mechanical ventilation
Prolonged stay in high-risk areas of hospitals [82]
Risk factors for MRSA mortality
Lung as the source of infection [52]
Unknown source of infection [52]
Occurrence of shock [52]
Increasing age [85]
APACHE III score 60 [86]
MRSA  methicillin-resistant Staphylococcus aureus; LOS  length of
stay; ICU  intensive care unit; APACHE III  Acute Physiology and
Chronic Health Evaluation III.
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diabetes, end-stage renal disease, prior antibiotic therapy,
and prior immunosuppressive therapy.
In patients who are candidates for anti-MRS therapy,
decisions have to be made regarding which antibiotic to use
and the method and length of administration of such an
agent. (Table 2 [available from author] provides a compar-
ative profile of key anti-MRS agents and is available from
the senior author on direct request.)
Vancomycin
Vancomycin is a glycopeptide antibiotic that exerts bac-
tericidal activity via inhibition of bacterial cell wall biosyn-
thesis. The only agent available until quite recently for
-lactam resistant gram-positive organisms, vancomycin,
has had a remarkably long duration of use. However, its
nephrotoxic side effects are a continuing concern [27].
Since it enhances the toxicity of aminoglycosides, it is
probable that vancomycin injures renal tubular epithelial
cells [28].
With the exception of the incidences of VRSA and VISA
noted above, virtually all strains of S aureus are susceptible
to vancomycin. The vast majority of CoNS are also suscep-
tible to vancomycin. Enterococci, however, are a different
issue, and the increasing prevalence of VRE among post-
surgical infections has become a major public health issue.
Vancomycin is bactericidal for most gram-positive patho-
gens, with minimum inhibitory concentrations (MICs) in
the range of 1 to 5 g/mL. For enterococci, vancomycin is
only bacteriostatic.
Quinupristin/dalfopristin
Quinupristin/dalfopristin is a combination of two strep-
togramins that exert activity via inhibition of protein syn-
thesis. Each component binds to the peptidyltransferase
domain of the bacterial ribosome with differing affinity and
actions [29]. The implication of this is that development of
resistance by susceptible organisms would be uncommon.
In practice, acquisition of resistance appears to occur at
rates observed with other agents, including vancomycin and
linezolid. Resistance may develop through decreased ribo-
somal binding, through inactivating enzymes, or through
efflux mechanisms [30]. In vitro analysis of the spectrum of
activity of Q/D has confirmed its relatively selective cov-
erage of gram-positive aerobic bacteria.
Individually, each component of the streptogramin has
bacteriostatic activity against staphylococci and strepto-
cocci, but together, the agents exhibit synergy leading to
bactericidal activity. The combination drug, however, is
bacteriostatic against Enterococcus faecium and has poor
activity against Enterococcus faecalis. Despite a short half-
life, an extended postantibiotic effect allows the agent to be
dosed every 8 to 12 hours.
Quinupristin/dalfopristin inhibits the cytochrome P450
3A4 pathway, and caution is warranted with concomitant
use of other medications eliminated via this pathway. Clin-
ical trials in patients with vancomycin-resistant E faecium
infections have documented efficacy [31]. The results of
comparative clinical trials suggest that Q/D has similar
efficacy to that of commonly used antibiotics, including
cefazolin, oxacillin, and vancomycin, in patients with skin
and skin-structure infections or nosocomial pneumonia. Ar-
thralgia, myalgia, nausea, diarrhea, vomiting, and rash are
the most frequently reported systemic adverse events [31].
Linezolid
Linezolid is a synthetic antibiotic that inhibits bacterial
protein translation at the initiation phase of protein synthesis
[32]. All linezolid active against MRSA and VRE (Table 3)
[33–37]. For vancomycin-susceptible enterococci, staphy-
lococci, and streptococci, the activity of linezolid appears
comparable to that of vancomycin [34]. Linezolid is rapidly
and completely absorbed after oral administration and
reaches peak plasma concentrations within 1 to 2 hours. At
steady state, minimum plasma concentrations following
standard dosing have been found to be above MIC90 con-
centrations for susceptible pathogens.
Linezolid has been found clinically efficacious in the
treatment of skin and skin structure, nosocomial pneumonia,
and bloodstream infections due to VRE [38,39]. It is gen-
erally well tolerated, with gastrointestinal disturbances be-
ing the most commonly occurring adverse event. Linezolid
can suppress the bone marrow in a time-dependent manner
Table 3
Antimicrobial activities of vancomycin, linezolid, and quinupristin-
dalfopristin against various bacterial strains [33]
Organism MIC90
Vancomycin
(range)*
Quinupristin/
Dalfopristin†
(range)
Linezoid‡
(range)
MSSA 2.0 (0.50–2.0) 1.0 (NA) 2.0 (1.0–2.0)
MRSA 2.0 (0.50–4.0) 1.0 (NA) 2.0 (0.25–4.0)
MSCoNS 2.0 (0.25–2.0) 0.5 (NA) 1.0 (0.25–2.0)
MRCoNS§ 2.0(0.5–4.0) 0.5 (NA) 2.0 (0.5–4.0)
VS E faecalis 2.0 (0.5–4.0) NA 2.0(0.5–2.0)
VR E faecalis 1024.0 (16.0–1024.0) NA 2.0 (1.0–2.0)
VS E faecium 2.0 (0.01–2.0) NA 2.0 (0.5–2.0)
VR E faecium 512.0 (16.0–1024.0) 1.0 (NA) 2.0 (1.0–2.0)
* Isolate counts as follows: MSSA (31), MRSA (50), MSCoNS (28),
MRCoNS (46), VS E faecalis (25), VR E faecalis (17), VS E faecium (27),
and VR E faecium (38).
† Isolate counts as follows: MSSA (2,140), MRSA (1051), MSCoNS
(940), MRCoNS (786), and VS E faecium (895).
‡ Isolate counts as follows: MSSA (31), MRSA (50), MSCoNS (28),
MRCoNS (46), VS E faecalis (25), VR E faecalis (17), VS E faecium (27),
and VR E faecium (38).
§ Includes 15 teicoplanin-resistant strains.
MIC  minimum inhibitory concentration; MSSA  methicillin-sus-
ceptible Staphylococcus aureus; MRSA  methicillin-resistant Staphylo-
coccus aureus; MSCoNS  methicillin-susceptible coagulase-negative
staphylococci; MRCoNS  methicillin-resistant coagulase-negative staph-
ylococci; VS  vancomycin susceptible; VR  vancomycin resistant; NA
 not available.
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[40]. Thrombocytopenia is the most common manifestation
of this phenomenon and occurred in approximately 2% of
patients in clinical trials. Discontinuation of linezolid results
in restoration of platelet counts to pretreatment levels in
patients for whom outcomes are known. As a precaution,
complete blood counts should be performed weekly in pa-
tients who require greater than 2 weeks of therapy, who are
at increased risk for bleeding, who have preexisting throm-
bocytopenia, or who receive other medications that may
cause thrombocytopenia.
Selection of therapy for presumed methicillin-resistant
staphylococci
In patients for whom an anti-MRS agent is indicated,
empiric treatment may be initiated with vancomycin, lin-
ezolid, or Q/D. Both institutional and individual risk factors
should be weighed in making the decision. Vancomycin or
teicoplanin (in Europe) may be the antibiotic of choice
when individual risks and institutional risks for VRE are
low (10%).
Selection of therapy when risk of vancomycin resistance
is present
Table 4 provides a list of risk factors associated with the
development of VRE. Vancomycin should not be prescribed
when institutional risks for VRE infections are high
(10%) or in cases in which an individual’s risk for VRE
acquisition is high. As with MRSA, there are no data that
indicate the cut-off points for vancomycin therapy. How-
ever, the same variables that define individual patient
thresholds for the assumption of resistance apply.
Problems associated with vancomycin therapy
Recent clinical studies have shown less than optimal
results in the treatment of bacteremia and endocarditis with
vancomycin [7,41,42]. Numerous reports have also docu-
mented that MRSA bacteremia may persist during vanco-
mycin therapy despite resolution of fever and may lead to
significantly delayed complications [43]. Another recent
study has also demonstrated that MRSA colonization of a
silastic rubber surface can occur even in the presence of
prophylactic vancomycin or rifampin [44].
Also of concern is the significant mortality rate, approxi-
mately 50%, in patients treated with vancomycin for MRSA
pneumonia [45]. In contrast, in patients receiving -lactams for
pneumonia caused by methicillin-susceptible S aureus
(MSSA), survival is the rule [46]. Because of difficulties in
clearly defining nosocomial pneumonia, particularly in venti-
lated patients, the outcome of bacteremia in patients with
pneumonia is of interest. A recent small observational (without
randomization) study reported high mortality rates in patients
treated with vancomycin for bacteremic nosocomial pneumo-
nia caused either by MRSA or MSSA [47]. In the group of
patients with MSSA pneumonia, infection-associated mortality
was found to be significantly higher among vancomycin-
treated patients (47%) than among those treated with cloxacil-
lin (0%, P0.01). Multivariate analysis showed a relationship
between mortality and the following variables: septic shock
(odds ratio [OR] 61), vancomycin treatment (OR 14), and
respiratory distress (OR  8). Similar concerns were articu-
lated by Moise et al [48]. Lack of lung tissue penetration may
be the underlying cause of treatment failure with vancomycin
in pneumonia.
Many smaller studies showing no difference between mor-
tality caused by MSSA and that caused by MRSA [49,50].
However, in a recent meta-analysis of 31 cohort studies pub-
lished between 1980 and 2000, MRSA bacteremia was shown
to be clearly associated with a higher mortality rate than MSSA
bacteremia [51]. This difference persisted when subanalyses
were done for length of stay (LOS) and severity of illness.
Other studies have documented higher mortality rates and
resource utilization with MRSA infections compared with
MSSA infections [7,52–54]. These studies only serve to high-
light the critical nature and multiple consequences of the prob-
lem of antibiotic resistance.
Tolerance and heteroresistance as potential mechanisms
for treatment failure
Treatment failures with vancomycin have prompted
studies investigating the phenomenon of tolerance to gly-
copeptides. Tolerance refers to persistence of nondividing
Table 4
Institutional and individual risk factors for VRE
Institutional risk factors for VRE emergence and transmission [87]
Antimicrobial pressure
Suboptimal clinical laboratory recognition and reporting
Unrecognized “silent” carriage and prolonged fecal carriage
Intrahospital and interhospital transfer of colonized patients
Introduction of unrecognized carriers from community settings
Inadequate compliance with hand-washing and barrier precautions
Environmental contamination
Workload [88]
Individual risk factors for VRE*
Previous vancomycin and/or multidrug antimicrobial therapy,
including third generation cephalosporins, anti-anaerobic drugs
[89,90]
Patient proximity to a VRE patient [91]
Prolonged duration of prior vancomycin therapy [92]
Immunosuppressed patient [93]
Presence of in-dwelling devices [66,94]
Prolonged ventilation support [93]
Prolonged ICU stay [95]
Long-term care [96,97]
Known colonization [98]
Prolonged preoperative in-hospital stay [99]
* Factor in potential adverse outcome to the individual patient of delayed
therapy.
VRE  vancomycin-resistant enterococci; ICU  intensive care unit.
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viable organisms. In clinical isolates of S aureus from pa-
tients with endocarditis or bacteremia, 7 of 15 MRSA iso-
lates, but only 2 of 20 MSSA isolates, were tolerant as
judged by time-kill experiments (P 0.04) [55]. Glycopep-
tide tolerance is a real phenomenon in S aureus, particularly
among MRSA isolates, and may compromise glycopeptide
therapy for serious S aureus infection. These observations,
together with the emergence of isolates with reduced sus-
ceptibility to glycopeptides, raise concern for continuing
therapy with vancomycin as standard therapy for pneumo-
nia or bacteremia caused by gram-positive cocci, especially
in critically ill patients in the absence of rapid clinical
response.
The significance of heteroresistant S aureus strains
remains to be analyzed. Heteroresistance refers to the
heterogenous or differential expression of resistance
within a colony. It was first noted with regard to methi-
cillin-resistant staphylococci and has been more recently
described for vancomycin/MRSA interaction. In hetero-
resistant populations, the majority of cells expresses re-
sistance to low concentrations of vancomycin, and a
minority of cells expresses resistance to much higher (8
g/mL) concentrations [56].
The MRSA strains characterized by heterogeneous van-
comycin resistance or hGISA have been well described
[13,14]. Vancomycin heteroresistance is inducible by -lac-
tam therapy. A case-control study to define risk factors for
heteroresistance identified: the time between admission and
onset of bacteremia, admission to the intensive care unit, the
prior use of vancomycin or -lactams, and the isolation of
methicillin-resistant staphylococci as significant risk factors
by use of univariate analysis [57]. Patients with bacteremia
due to staphylococci with heteroresistance to vancomycin
had an overall mortality rate of 44%, compared with a
mortality rate of 10% among patients with staphylococcal
bacteremia without vancomycin heteroresistance.
At present, routine laboratory detection of S aureus with
intermediate resistance and heteroresistance is difficult, and
procedures are not yet standardized. Screening for vanco-
mycin resistance is done by conventional methods or by the
disk-agar method that uses vancomycin-salt agar to demon-
strate satellitism around an aztreonam disk, leading to the
determination of vancomycin MIC by Etest [57].
VRE prevalence
The NNIS system has reported that 25% of enterococci
are vancomycin resistant [58]. Given the propensity of en-
terococci to develop multidrug resistance, the panel agreed
that an institutional incidence of resistance of 10% should
be considered high. Patients with individual risk factors for
VRE infection requiring empiric therapy in such institutions
should receive therapy active against VRE [45,49].
Enterococcal resistance to antibiotics
Compared with streptococci, enterococci are relatively
resistant to penicillin, ampicillin, and the ureidopenicillins,
with MICs of 1 g/mL to 8 g/mL and even higher for most
E faecium. Enterococci are also inherently resistant to other
antibiotics, including cephalosporins, the semisynthetic
penicillinase-resistant penicillins, and have developed plas-
mid- and transposon-mediated resistance to tetracyclines,
erythromycin, azithromycin, clarithromycin, chlorampheni-
col, trimethoprim, and clindamycin. Enterococcal resistance
to aminoglycosides results from the ability of enterococci to
block the uptake of the drug at the cell wall [60]. Conse-
quently, aminoglycosides are only effective against entero-
cocci when used in combination with cell-wall-active anti-
biotics. This combination treatment has been compromised,
however, by the rapid spread of high-level aminoglycoside
resistance among enterococci (2,000 g/mL). This degree
of resistance predicts an absence of synergism between
cell-wall-active agents and the aminoglycoside. The mech-
anism of high-level resistance is the result of a bifunctional
enzyme, which is capable of inactivating different amino-
glycosides [61].
Genetics of vancomycin resistance in enterococci
The propensity of E faecalis to acquire multiple antibi-
otic-resistance traits is in part due to the existence of mul-
tiple mechanisms for exchanging genetic material (conju-
gation). The best-studied system of conjugation involves
oligopeptides called pheromones and pheromone-respon-
sive plasmids. Briefly, strains of E faecalis secrete into the
culture medium a variety of small peptide sex pheromones
specific for different types of plasmids. When a bacterium
containing a pheromone-responsive plasmid (the potential
donor cell) comes into contact with its corresponding pher-
omone, there is transcription of the specific plasmid gene,
resulting in the expression of a peptide called “aggregation
substance” on the cell surface. When this bacterium subse-
quently collides with another E faecalis, the aggregation
substance interacts with a corresponding binding substance
on the surface of the colliding cell, bonding the two bacte-
rial cells together. Such bonding provides a physical chan-
nel for the transference of the pheromone-responsive plas-
mid from the donor bacterium to the colliding or recipient
bacterium. Once the recipient cell has acquired the plasmid,
the passage of the resistance trait is complete and synthesis
of the corresponding sex pheromone is shut off. Other
conjugation systems involving a broad range of plasmids
have also been implicated in the transfer of resistance
among species of enterococci and other gram-positive or-
ganisms such as streptococci and staphylococci.
An additional type of conjugation, which involves con-
jugative transposons, may explain the spread of resistance
genes to many different species [62]. Conjugative trans-
posons also encode the ability to bring about conjugation
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between different bacterial cells. They insert into the chro-
mosome or into a plasmid of the new host. Other resistance
genes, including those encoding resistance to erythromycin
and kanamycin, are also found on conjugative transposons.
There are reports of the vanB gene cluster within large
conjugative chromosomal elements that appear similar, at
least in function, to conjugative transposons [63]. One of the
more frightening issues being contemplated with regard to
vancomycin resistance in enterococci is the clinical conse-
quence if and when these transferable vancomycin resis-
tance operons make the genus jump from Enterococcus to
organisms such as S aureus (including MRSA) and Strep-
tococcus pneumoniae. Transfer of VRE genes from the
enterococci to other bacteria has already occurred in nature,
and investigators have demonstrated the transferability of
the vanA operon from Enterococcus into other species,
including S aureus, in the laboratory.
Biochemistry of vancomycin resistance
In vancomycin susceptible strains, the binding of vanco-
mycin to D-alanine-D-alanine (D-ala) termini of pepti-
doglycan precursors prevents their cross-linking to adjacent
strands. This significantly weakens the structural integrity
of the cell wall and leads to osmotic lysis. Vancomycin
resistance in enterococci is the result of the production of
peptidoglycan precursors that terminate in D-ala-D-lactate
instead of D-ala-D-ala, and these altered peptidoglycan pre-
cursors show greatly decreased binding affinity for glyco-
peptide antibiotics [64]. Two major, genetically distinct
forms of acquired resistance, vanA and vanB, are located on
transposable elements and respectively confer high-level
resistance to both vancomycin and teicoplanin or to vanco-
mycin alone [65].
The major risk factor for systemic infection with VRE is
gastrointestinal colonization by VRE. One predisposing fac-
tor for gut colonization by VRE is the use of oral or
parenteral antimicrobial agents with activity against anaer-
obes. In a recent study, oral or parenteral metronidazole, but
not vancomycin, was correlated with VRE bacteremia
[66,67]. This finding is of concern because metronidazole
has recently been advocated over oral vancomycin as the
drug of choice for antibiotic-induced colitis, with the rea-
soning that oral vancomycin would predispose to gut colo-
nization with VRE.
Duration of treatment
How long should treatment be continued in patients
initiated with empiric antibiotic therapy? In general, treat-
ment should be continued and driven by culture and sus-
ceptibility data and should be stopped or changed based on
these results.
Treatment should also be guided by patient response.
Any treatment may be considered unsuccessful if there is a
lack of clinical response in 72 hours, as indicated by the
persistence of fever, high white blood cell count, and other
signs of systemic infection such as persistent bacteremia.
Persistent organ dysfunction, whether at the site of infection
or not, may also be indicative of treatment failure. The
status of therapy may be periodically assessed with cultures,
particularly for infections in debilitated or immunocompro-
mised patients where prolonged treatment (7 days) may
be required. Such patients are at greatest risk of acquisition
of resistance on therapy [68,69]. Resistance has occurred
primarily in patients who did not have a foreign body (eg, a
peritoneal dialysis catheter) removed. The panel believes
that measurement of the rate of pathogen clearance from
quantitative cultures should be explored as an index of
treatment response.
Since oral formulations of -lactams and linezolid are
available, on-going patient evaluation should include con-
sideration of oral therapy. This alternative may have the
potential to reduce hospital LOS. Although there appears to
be a reluctance to use oral therapy in seriously ill patients,
the efficacy and bioavailability (100%) of linezolid now
make therapy possible in those patients who do not require
hospitalization but otherwise require parenteral vancomycin
therapy [70,71]. The panel recommends that conversion to
oral therapy be considered in patients in whom discharge is
eminent (within 48 hours) as long as they meet common
criteria for oral drug administration (functioning gastroin-
testinal tract, absence of hypotension, absence of evidence
of multiple organ dysfunction syndrome).
Cost of newer therapies
Acquisition costs for both linezolid and Q/D are substan-
tially higher than acquisition costs for vancomycin. Per day
of intravenous therapy, the cost of linezolid and Q/D are
approximately $140 and $320, respectively [72]. Oral lin-
ezolid is slightly less expensive (approximately $106) than
the intravenous formulation per day of therapy. However, a
significant proportion of the overall cost of treating a serious
infection is incurred from the patient occupying a hospital
bed [73]. Data collected from several studies of linezolid
and Q/D have determined that hospital length of stay is 1 to
2.5 days shorter with linezolid or Q/D compared with van-
comycin, oxacillin, and cefazolin [74–76]. In addition, be-
cause there is no oral alternative to vancomycin other than
linezolid, mean and median durations of intravenous treat-
ment were significantly shorter (P.001) for patients
treated with linezolid (n  240) compared with patients
treated with vancomycin (n  220), with a mean difference
of 5.6 days in the intent-to-treat sample [75]. The combined
duration of intravenous and oral therapy for patients treated
with linezolid was slightly longer compared with patients
treated with vancomycin (13.1 days versus 11.8 days; P 
0.06). Although the acquisition costs of linezolid and Q/D
are higher than those for vancomycin, there may be other
economic benefits to using these drugs such as fewer days in
the hospital, and, in the case of linezolid, fewer days of
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intravenous therapy with its associated nursing and phar-
macy costs.
Conclusions
Drug resistance among gram-positive pathogens is cur-
rently an endemic problem and is prevalent across antibiotic
classes. The mechanisms of -lactam resistance among
gram-positive organisms are substantially different than
those found in gram-negative organisms. This is also true
for vancomycin-resistant organisms. The genetics and bio-
chemistry of vancomycin resistance are central to determin-
ing the likelihood of continued spread of these organisms
and the probability that this characteristic will be passed on
to other organisms. With its propensity to acquire new traits,
such as high-level gentamicin, penicillin, and vancomycin
resistance, the enterococcus continues to create new thera-
peutic problems and dilemmas. Its ability to transfer plas-
mids to streptococci and staphylococci and the implications
of a possible spread of penicillin and vancomycin resistance
to these and other gram-positive species are also of concern.
It is unclear whether a campaign to reduce vancomycin
usage will be successful as a strategy to control the spread
of vancomycin resistance. The availability of linezolid and
Q/D offers new options for treatment of gram-positive in-
fections. By instituting proper in-house control guidelines
against infection, implementing methods for appropriate
antibiotic usage, and developing models for reduction of
resistance against these new agents, it is hoped that the
utility of these new antibiotics will be extended.
We have focused on postsurgical infections and high-
lighted the decisions that need to be made in selecting
appropriate antibiotics, routes of administration, duration of
treatment, and assessment of efficacy of treatment. Empiric
therapy should be initiated early in the course of infection in
all seriously ill patients. The choice of therapy should flow
from -lactams to vancomycin to parenteral linezolid or
Q/D. In patients in whom discharge is anticipated, and who
are candidates for oral therapy, oral linezolid is an option for
the treatment of resistant gram-positive infections. We em-
phasize an approach to provide antibiotic therapy that will
cover the most virulent species, identified by risk factors,
with subsequent coverage that will target culture-identified
organisms. While many gaps remain in our knowledge, we
hope that the decision tree presented here contributes to a
logical treatment approach, one in which decisions are made
after weighing both individual and institutional risks for
colonization and resistance.
Future directions
The panel recommends that diligent institutional surveil-
lance and resistance data be maintained so that treatment
decisions can be made logically and problems of resistance
can be identified early in development. Although we have
recommended that an MRSA prevalence rate 20% and
VRE prevalence 10% should be considered high in any
institution, we recognize that research is needed to validate
such cut-off points.
With the availability of newer agents, it has become
possible to tailor therapy to the specific patient, the partic-
ular site of infection, and the specific pathogen. These
options provide treatment alternatives that may prevent spe-
cific organ toxicities (eg, nephrotoxicity from vancomycin)
or permit drug accumulation at an infection site. This may
improve efficacy for that agent (eg, at pulmonary epithelial
lining for the treatment of pneumonia or on the skin for
cellulitis). Combination therapies are currently under inves-
tigation as are antibiotic cycling programs. Their relative
success remains to be established. Exposure to antibiotics
with differing mechanisms of action also implies a reduc-
tion in resistance selection pressure, a development that
should be welcomed. Another area that could use additional
research is the necessary duration of treatment for specific
infections and evidence to support specific stopping criteria.
It is possible that serial quantitative cultures, particularly for
pulmonary infections, could prove to be useful in this con-
text.
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